## Management of Benign High Risk Breast Lesions

Eun Yeong Oh, MD, PhD

Subspecialty Chief of Breast Pathology and Immunohistochemistry Laboratory MidAtlantic Permanente Medical Group Regional Laboratory

#### Introduction

Benign high risk breast lesions that are typically excised if diagnosed in a CNB: Atypical ductal hyperplasia (ADH) Flat epithelial atypia (FEA) Lobular neoplasm (ALH/LCIS) Intraductal Papilloma (IDP) Radial scar/complex sclerosing lesion (RS/CSL) Mucocele-like lesion (MLL) Fibroepithelial lesion with increased stromal cellularity Spindle cell neoplasm Microglandular adenosis

#### Lifetime Risk and Upgrade Rates to Malignancy in Subsequent Excision

	Lifetime Risk
ADH	3-5 X
Papilloma with atypia	7-8 X
MLL with atypia	
LCIS	8-10 X
ALH	3-5+ X
FEA	1.5-2 X
RS/CSL	2 X
Benign IDP	1-2X
MLL without atypia	

Management for many benign high risk lesions are <u>evolving</u> due to low upgrade rates to malignancy in subsequent excision

Could we characterize subset(s) of patients who could be managed <u>non-surgically</u>?

Flat epithelial atypia (FEA) Lobular neoplasm (ALH/LCIS) Intraductal Papilloma (IDP) Radial scar/complex sclerosing lesion (RS/CSL) Mucocele-like lesion (MLL)

## Flat Epithelial Atypia (FEA)

#### Low grade DCIS



### ADH arising in a background of FEA and Ca<sup>++</sup>



### Management of FEA diagnosed on a CNB

- Mean upgrade rate to <u>malignancy</u> on excision is 8% (0-21%)
- ▶ 1% upgrade rate excluding rad-path discordant cases (El Khoury et al )
- Studies have shown no upgrade on excision where no residual calcifications present after CNB
- Watchful surveillance may be acceptable for FEAs without residual calcifications or associated mass
- Radiology-Pathology Correlation is Strongly Advised

Calhoun et. al. Modern Pathology (2015) 28, 670-676

Mooney et. al. Modern Pathology (2016) 29, 1471-1484

El Khoury et. al. Br J Radiol (2017) 90, 1072

## Lobular Neoplasm (LCIS and ALH)



## LCIS, classic type

8.0

#### **ALH**

### ALH with pagetoid involvement of a duct



### LCIS with necrosis and calcifications



### **Pleomorphic LCIS**



Management of Lobular Neoplasm

#### Mooney et al (2016)

- ▶ Mean upgrade rate is <u>9%</u> (0-67%) for ALH and <u>18%</u> (0-60%) for LCIS
- Incidental ALH or LCIS on CNB: 5% upgrade rate to malignancy
- Targeted ALH or LCIS on CNB: 30% upgrade rate to malignancy
- Recent studies also suggest that surgical excision may not be mandatory for lobular neoplasm when it is <u>an incidental finding</u> and there is <u>concordance</u> <u>between radiologic and pathological findings</u> regarding the targeted biopsied lesion
- LCIS variants (LCIS with necrosis and pleomorphic LCIS) and <u>targeted LCIS/ALH</u> (mass or associated calcs) should be excised
- Radiology-Pathology Correlation is Strongly Advised

# Intraductal Papilloma





### **Benign Intraductal Papilloma**



### Sclerosed papilloma



### **Encapsulated Papillary Carcinoma**



### Solid Papillary Carcinoma



#### **DCIS with Papillary Growth Pattern**



#### **Management of Papillomas**

- Mean upgrade rate for <u>benign intraductal papilloma</u> is 4% (0-10%)
- Mean upgrade rate for atypical papilloma is 28% (15-68%)
- Inconsistent results regarding radiologic features associated with benign IDPs that may be upgraded to malignancy on excision
- No increased risk for sclerosed papillomas
- Watchful surveillance may be acceptable for benign IDPs without worrisome radiologic features
- Excisional biopsy for IDPs with atypia, adjacent calcifications, associated irregular/ill-defined mass or when radiologic and pathological findings are discordant

## Radial Scar/ Complex Sclerosing Lesion

#### Radial Scar



#### **Radial Scar with DCIS**





#### Radial Scar (RS)/ Complex sclerosing lesion (CSL)

- 2X increased breast cancer risk (> 50 years old)
- Mean of 7% upgrade rate to malignancy on excision (0-16%)
- Although there is no consensus on management of radial scar without atypia, excisional biopsy is usually performed

#### Mooney *et al* (2016, UCLA):

- RS < 5 mm or incidental are less likely to be upgraded in the excision</p>
- Watchful surveillance may be acceptable for incidental and small radial scars seen on CNB
- Conservative excision for lesions > 5 mm

## **Mucocele-like Lesion**

#### MLL with associated calcifications



#### MLL with benign epithelial hyperplasia and associated calcifications





#### DCIS with extracellular mucin production



#### Invasive mucinous carcinoma





Hum Pathol. 2016 March ; 49: 33–38

#### Management of MLL

- Mean upgrade rate of MLL without atypia is 4% (small sample size of published studies; Rakha et al Histopathology (2013); Sutton et al AJCP (2012))
- MLL without atypia may be managed with imaging surveillance, if no residual calcification or suspicious mass not present

- Mean upgrade rate for MLL with atypia is 21% (0-100%) and warrants an excisional biopsy for further evaluation
- Radiology-Pathology Correlation is strongly advised

## Summary

### Excisional biopsy for

- ADH
- FEA with residual calcifications or mass
- Intraductal papilloma with atypia, adjacent calcs, or irregular borders
- Targeted ALH and LCIS, and LCIS variants
- Targeted radial scars (> 5mm) and complex sclerosing lesion
- MLL with atypia or residual calcifications
- Discordant radiologic and pathological findings

## Summary

Watchful surveillance may be acceptable for

- FEA without residual calcifications or associated mass
- Incidental ALH and LCIS
- Intraductal papilloma without atypia or associated calcifications
- MLL without atypia, residual calcification or associated mass
- Small/incidental radial scar (< 5mm ?)</p>





## Questions?